UK markets closed
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • FTSE 250

    22,522.18
    +50.14 (+0.22%)
     
  • AIM

    1,254.25
    +6.12 (+0.49%)
     
  • GBP/EUR

    1.1540
    +0.0029 (+0.25%)
     
  • GBP/USD

    1.3840
    +0.0056 (+0.41%)
     
  • BTC-GBP

    39,841.04
    -4,574.34 (-10.30%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • DOW

    34,200.67
    +164.68 (+0.48%)
     
  • CRUDE OIL

    63.07
    -0.39 (-0.61%)
     
  • GOLD FUTURES

    1,777.30
    +10.50 (+0.59%)
     
  • NIKKEI 225

    29,683.37
    +40.68 (+0.14%)
     
  • HANG SENG

    28,969.71
    +176.57 (+0.61%)
     
  • DAX

    15,459.75
    +204.42 (+1.34%)
     
  • CAC 40

    6,287.07
    +52.93 (+0.85%)
     

Global Radiopharmaceutical Market (2020 to 2025) - by Type, Application, Procedure, End-user and Geography

Research and Markets
·8-min read

Dublin, March 15, 2021 (GLOBE NEWSWIRE) -- The "Global Radiopharmaceutical Market (2020-2025) by Type, Application, Procedure, End-User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

The Global Radiopharmaceuticals Market is estimated to be USD 6.3 Bn in 2020 and is expected to reach USD 7.9 Bn by 2025, growing at a CAGR of 4.5%.

Factors such as high demand for nuclear medicine such as SPECT and PET scan towards the diagnosis of diseases like cancer and other chronic diseases and increasing patient awareness for accuracy in the diagnosis have led to being a major driver of growth for this market. An increase in the prevalence of cancer and increased use of medical imaging as a diagnostics procedure is fuelling the growth of the market.

The high cost of developing radiopharmaceuticals relative to the return on investment, stringent regulatory requirements are restraining the growth of the radiopharmaceuticals market. The increase in R&D activities with technological advancement and strategic partnerships in the market are expected to create ample opportunities in the radiopharmaceuticals market.

Market Dynamics

Drivers

  • High Demand for Early Diagnosis in the Event of Cancer and Cardiovascular Chronic Diseases

  • Rising Healthcare Expenditure

  • Alpha Radio-Immunotherapy-Based Targeted Cancer Treatment

  • Initiatives to Lessen The Demand-Supply Gap of Isotopes

Restraints

  • Stringent Regulatory Guidelines

  • The High Cost of Devices Using Radioisotopes

  • The Short Half-Life of Radiopharmaceuticals

Opportunities

  • Use of Radiopharmaceuticals In Neurological Applications

  • Growing Awareness about the Benefits of Radiopharmaceuticals amongst Healthcare Providers

  • Technological Advancements

Challenges

  • Hospital Budget Cuts and High Equipment Prices

Trends

  • Increasing Preference of Spect and Pet Scans

Segmentation

By Type, Diagnostic Nuclear Medicine is estimated to account for the fast-growing segment during the forecasted period. The diagnostic nuclear medicine is further subdivided into Spect and PET Radiopharmaceuticals. Out of which Spect segment is assumed to hold the highest share in the forecasted period due to its wide availability and low cost.

By Application, the Oncology segment is estimated to account as the fast-growing segment during the forecasted period due to the increasing prevalence of cancer across different age groups. Also, one of the popular diagnostic techniques i.e, PET procedure, is increasingly being adopted for the diagnosis of cancer due to high imaging capabilities.

By End-User, the Hospital segment is estimated to account as the fast-growing segment during the forecasted period. It is mainly due to the rise in the adoption of various imaging technologies that involve PET scan or MRI Scan, along with the increasing presence of qualified medical practitioners in the radiology department across the globe.

By Procedure, Diagnostic Procedure consisting of SPECT and PET type of diagnosis is estimated to account as the fast-growing segment during the forecasted period. It is mainly due to the uncertainties in the production of other nuclear medicine that has led to the sifting trend towards PET procedures. Also, advancement like hybrid imaging systems such as PET-CT and PET-MRI has further boosted the growth of this segment.

By Region, North America is anticipated to lead the market. The factors attributed to the growth of the market are the increasing prevalence of cancer, technological advancements, and the high availability of radiopharmaceuticals, and the popularity of nuclear medicine among physicians.

The Global radiopharmaceutical market is further segmented based on Type, Application, Procedure, End-User, and Geography.

Company Profiles

Some of the companies covered in this report are GE Healthcare, Bayer Healthcare, Cardinal Health Inc., Eczacibasi-Monrol Nuclear Products, Bracco Imaging S.p.A, Nordion Inc., Lantheus Medical Imaging Inc., Advanced Accelerator Applications S.A, Mallinckrodt plc, and IBA Molecular Imaging.

Competitive Quadrant
The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Lions: Represents companies with a strong foothold in the market, with the highest market share, large investments in technologies, new products.
Bulls: Companies that are medium in size competing with their USPs, growing companies with proven market share.
Rabbits: Small companies but growing rapidly, constantly improving their offerings in the market.
Tortoise: Companies that are slow in growth, having a long legacy, and stable or negative in performance.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Radiopharmaceuticals Market.

  • The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.

  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.

  • The report includes in-depth market analysis using Porter's 5 force model and the Ansoff Matrix. The impact of Covid-19 on the market is also featured in the report.

  • The report also contains a competitive analysis using Positioning Quadrants, a Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market including parent industry

  • Important market dynamics and trends

  • Market segmentation

  • Historical, current, and projected size of the market based on value and volume

  • Market shares and strategies of key players

  • Recommendations to companies for strengthening their foothold in the market

Key Topics Covered:

1 Report Description

2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.3 Market Size Estimation
2.4 Assumptions of the Study
2.5 Limitations of the Study

3 Executive Summary

4 Market Overview
4.1 Introduction
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.3 Trends

5 Market Analysis
5.1 Porter's Five Forces Analysis
5.2 Impact of COVID-19
5.3 Ansoff Matrix Analysis

6 Global Radiopharmaceuticals Market, By Type
6.1 Introduction
6.2 Diagnostic Nuclear Medicine
6.2.1 Spect Radiopharmaceuticals
6.3.1.1 Tc-99m
6.3.1.2 Tl-201
6.3.1.3 Gallium (Ga-67)
6.3.1.4 Iodine-(I-123)
6.3.1.5 Other Spect Isotopes
6.2.2 Pet Radiopharmaceuticals
6.3.2.1 Fludeoxyglucose F-18
6.3.2.2 Rubidium (Ru-82)
6.3.2.3 Other Pet Isotopes
6.3 Therapeutic Nuclear Medicine
6.3.1 Alpha Emitters
6.3.1.1 Ra-223
6.3.2 Beta Emitters
6.3.2.1 Iodine (I-131)
6.3.2.2 Yttrium (Y-90)
6.3.2.3 Samarium (Sm-153)
6.3.2.4 Rhenium (Re-186)
6.3.2.5 Lutetium (Lu-177)
6.3.2.6 Other Beta Emitters
6.3.3 Brachytherapy Isotopes
6.3.3.1 I-125
6.3.3.2 Ir-192
6.3.3.3 Pd-103
6.3.3.4 Cs-131
6.3.3.5 Other Brachytherapy Isotopes

7 Global Radiopharmaceuticals Market, By Application
7.1 Introduction
7.2 Oncology
7.3 Cardiology
7.4 Gastroenterology
7.5 Neuroendocrinology
7.6 Neurology
7.7 Nephrology
7.8 Others

8 Global Radiopharmaceuticals Market, By Procedure
8.1 Introduction
8.2 Diagnostic Procedure
8.2.1 Spect Radiopharmaceuticals
8.2.2 Pet Radiopharmaceuticals
8.3 Therapeutic Procedure
8.3.1 Beta Emitters
8.3.2 Alpha Emitters
8.3.3 Brachytherapy Isotopes

9 Global Radiopharmaceuticals Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Ambulatory Surgical Centers
9.4 Diagnostics Centres
9.5 Research Institutes

10 Global Radiopharmaceuticals Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 South America
10.3.1 Brazil
10.3.2 Argentina
10.4 Europe
10.4.1 UK
10.4.2 France
10.4.3 Germany
10.4.4 Italy
10.4.5 Spain
10.4.6 Rest of Europe
10.5 Asia-Pacific
10.5.1 China
10.5.2 Japan
10.5.3 India
10.5.4 Indonesia
10.5.5 Malaysia
10.5.6 South Korea
10.5.7 Australia
10.5.8 Russia
10.5.9 Rest of APAC
10.6 Rest of the World
10.6.1 Qatar
10.6.2 Saudi Arabia
10.6.3 South Africa
10.6.4 United Arab Emirates
10.6.5 Latin America

11 Competitive Landscape
11.1 IGR Competitive Quadrants
11.2 Market Share Analysis
11.3 Competitive Scenario
11.3.1 Mergers & Acquisitions
11.3.2 Agreements, Collaborations, & Partnerships
11.3.3 New Product Launches & Enhancements
11.3.4 Investments & Fundings

12 Company Profiles
12.1 GE Healthcare
12.2 Eckert & Ziegler Group
12.3 Jubilant Life Sciences
12.4 Mallinckrodt Pharmaceuticals
12.5 Bracco Imaging S.p.A
12.6 Nordion, Inc
12.7 NTP Radioisotopes SOC Ltd.
12.8 Cardinal Health
12.9 Curium
12.10 Bayer
12.11 Lantheus Medical Imaging
12.12 The Institute of Radioelements
12.13 Australian Nuclear Science & Technology Organization
12.14 Eczacibasi-Monrol
12.15 Advanced Accelerator Applications S.A
12.16 IBA Molecular Imaging

13 Appendix
13.1 Questionnaire

For more information about this report visit https://www.researchandmarkets.com/r/hg9u3c

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900